secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107740
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports Q3 net loss $65.7M; aleniglipron data on track for year-end 2025
--------------------------------------------------------------------------------

- Net loss of $65.7M in Q3 2025 vs. $34.0M in Q3 2024; R&D expenses rose to $59.0M from $32.6M.
- Cash, cash equivalents and short-term investments totaled $799.0M as of Sep 30, 2025, expected to fund operations through at least 2027.
- Topline 36-week data from aleniglipron ACCESS and ACCESS II Phase 2 studies expected by year-end 2025.
- Phase 1 study of oral amylin receptor agonist ACCG-2671 anticipated by year-end 2025; second amylin candidate ACCG-3535 declared.
- GAAP net loss per share not disclosed; non-cash share-based compensation was $7.5M in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/0001104659-25-107740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925107740/tm2530323d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer